



# CEE UPDATES

## August 2024

### ACE VALUE-BASED HEALTHCARE CONFERENCE BREAKOUT SESSION FOR PATIENTS AND CARERS

During the ACE Value-Based Healthcare Conference on 23 August 2024, the CEE team held a breakout session titled **“Co-creating Meaningful Patient Engagement in Healthcare”** with participation from more than 100 representatives from patient organisations and support groups, public healthcare institutions and the industry. Attendees enjoyed insightful presentations and discussions from the esteemed panellists about their healthcare journeys and the remarkable contributions they have made to include patients as essential partners in policy development and healthcare decision-making.



“Hearing directly from speakers regarding patient engagement in Singapore and overseas was the most relevant to me. There was also in-depth discussions on topics. Great speakers!”

“

*There was an emphasis on patient involvement in all aspects of healthcare. The sharing of personal experiences by the panellists inspire and motivate me to be part of the patient advocate and engagement journey to enhance the quality of life for patients and caregivers. Thank you for the inspiring stories!*

”



“

*Patient engagement is already taking place overseas and Singapore is headed that way too. This session gave me new perspectives on what is important in engaging patient advocates. Appreciate the sharing and networking opportunity.*

”




**We would like to thank all panellists and participants for contributing to the breakout session. See you at our future events!**

# CONTRIBUTING TO A REGIONAL INITIATIVE

## Asia Pacific Oncology Alliance (APOA) Hackathon, 27 to 28 August 2024

The CEE team and two ACE Consumer Panel members participated in a hackathon to identify opportunities to drive broader implementation of the [APOA framework](#) and improve cancer care and survivorship in the Asia Pacific. With over 40 experts from across the cancer continuum, the team highlighted patient-centric approaches to healthcare decision making in Singapore and participated in inspiring discussions on collaborative and tangible ways to implement the framework and create better outcomes for people diagnosed with cancer.



# SHARING ACE'S PATIENT INVOLVEMENT PROCESSES AND EXPERIENCES

## 13<sup>th</sup> Singapore-International Physiotherapy Congress, 14 July 2024

At this conference, the CEE team was invited to share insights and discuss important considerations on patient involvement in health technology assessment during one of the symposiums titled "*Patient and Public Engagement in Integrated Knowledge Translation Research: Are we there yet?*"




# SHOWCASING SINGAPORE'S PATIENT INVOLVEMENT EFFORTS INTERNATIONALLY

Three posters from the CEE team were presented virtually at the Health Technology Assessment international (HTAi) Annual Meeting from 15 to 19 June 2024. A summary of each poster is provided below, and you can view the posters on the [ACE website](#).

## 1. Does Patient Input Add Value to Healthcare Decision-Making?

During the first two years of patient involvement in HTA in Singapore, a high proportion of ACE's HTAs (around 89%) were informed by patients' lived experiences, which have helped decision-making committees understand how different conditions affect patients and their carers and have informed funding recommendations of various health technologies.



## 2. A New Process For Patients And Caregivers To Suggest Health Technologies For Funding Consideration In Singapore

The inclusion of patients and carers in the topic prioritisation process provided valuable alternative perspectives that helped identify health technologies which could address unmet clinical needs. The minimal overlap between topics suggested by patients and clinicians highlights that patients and carers may perceive clinical need differently from clinicians.

## 3. Impact Of A Consumer Panel To Inform Health Technology Assessments And Policy Development: The Singapore Experience

During their first term, the ACE Consumer Panel was instrumental in co-developing processes to ensure meaningful patient involvement in HTA and policy development, championing ACE's work, providing advice on priority setting, and fostering collaborations between ACE and patient organisations. Members also valued many aspects of being on the Panel.



**We would like to thank all patient organisations who have been involved in ACE's work so far. Your contributions have helped ensure that the patient voice is integral to our processes and the work we do addresses patients' needs and leads to better outcomes.**

# 69

## PATIENT RESPONSES WERE GATHERED FOR TOPICS PRESENTED TO THE MOH ADVISORY COMMITTEES IN JULY 2024




The effort put in by patients to share their experiences is appreciated and every input is valuable to ACE and MOH. The CEE team notifies patient organisations of the advisory committees' funding recommendations after each meeting and provides feedback on which information provided by patients was most helpful to inform the committees' deliberations. The CEE team also invites suggestions on how the patient involvement processes can improve.

## PATIENT FACTSHEETS

### 7 PATIENT FACTSHEETS PUBLISHED SINCE MAY 2024

FIND OUT MORE

- Allopurinol for treating gout
- Combination eye drops for open-angle glaucoma
- Continuous Glucose Monitoring systems for type 1 diabetes
- Injectable drugs for preventing migraine
- What are cell, tissue, and gene therapies?
- Oral treatments for type 2 diabetes (updated)
- Treatments for chronic lymphocytic leukaemia (updated)



Patient factsheets are co-developed with patient organisations and clinicians to equip patients with helpful and evidence-based information about different medical conditions and encourage shared decision-making with their doctors about their healthcare needs.

We would like to thank members from the patient organisations for providing feedback and suggestions to help inform the content and layout of these factsheets.


## 11 NEW PLAIN ENGLISH SUMMARIES PUBLISHED SINCE JUNE 2024

Plain English summaries (PES) provide brief information about the treatments and conditions that have been evaluated by ACE and describe the key funding recommendations made by the MOH advisory committees.

**FIND OUT MORE**

### Newly published PES:

- Burosumab for X-linked hypophosphataemia
- Continuous glucose monitoring systems for children and adults with type 1 diabetes mellitus
- Drug treatments for spinal muscular atrophy
- Enzyme replacement therapies for treating Fabry disease
- Monoclonal antibodies for preventing migraine
- Ruxolitinib for treating graft-versus-host disease
- Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
- Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma
- Tolvaptan for treating autosomal dominant polycystic kidney disease
- Trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
- Tafamidis for treating transthyretin amyloid cardiomyopathy (updated)



## COMING SOON



The annual call for topics will be open from **October 2024**. Patients, carers and patient organisations will be invited to suggest which health technologies they would like ACE to evaluate. All patient organisations will receive an application form from the CEE team. Stay tuned for more details!

The **Consumer Engagement and Education (CEE)** team supports patient involvement in ACE's work and co-develops plain English summaries and educational resources with patient organisations to improve health literacy and encourage shared healthcare decision-making between patients and their doctors. Tell us what matters to you, your organisation or your community. Email us at [ACE\\_CEE@moh.gov.sg](mailto:ACE_CEE@moh.gov.sg).

